Drug Trial Radar · NCT07507760
Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jun 12, 2026
Primary completion
Apr 2029
Study completion Apr 2029
Sponsor
- Lead sponsor
- PETHEMA FoundationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if the combination of oral decitabine plus ivosidenib works to treat naïve adult patients with acute myeloid leukemia (AML) with IDH1 R132 mutation older than 60 years old or those who are older than 18 years old with defined comorbidities that make them not suitable for standard induction therapy. The main objectives of this clinical trial are: * Asses the Complete Remission (CR) and Complete Remission with incomplete marrow recovery (CRi) rates of this treatment. * Determine the incidence and severity of all adverse events (AEs). All participants will receive oral ivosidenib and oral decitabine in treatment cycles of 28 days until disease progression, lack of clinical benefit or the end of the study. Patients who achieve CR/CRi will be elegible to receive allogeneic stem cell transplantation.
Conditions
- Acute Myeloid Leukemia With Gene Mutations
Interventions
Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLETDrug
Oral Decitabine (Decitabine/Cedazuridine 35 Mg-100 Mg) will be administerd on Days 1-5 of each treatment cycle
Ivosidenib Oral TabletDrug
Ivosidenib 500 mg/orally on Days 1-28 of each treatment cycle
HydroxyureaDrug
0.5-6 gram/day orally during the screening period and the two first treatment cycles if hyperleukocytosis at diagnosis
CytarabineDrug
Maximum 1 gram/sqm/day during the screening period and the two first treatment cycles if hyperleukocytosis at diagnosis
Allogeneic stem cell transplantationProcedure
Only for those participants achieving CR/CRi
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of CR/CRiTime frame: 3 years
Locations
21 sites in 2 countries. Site status is shown where the registry gives one.
ULS Região de Aveiro
Aveiro, Portugal · Not yet recruiting
Hospital Central do Funchal
Funchal, Portugal · Not yet recruiting
Hospital Santa Maria
Lisbon, Portugal · Not yet recruiting
ULS São José
Lisbon, Portugal · Not yet recruiting
Hospital Pedro Hispano
Porto, Portugal · Not yet recruiting
Complejo Hospitalario de Albacete
Albacete, Spain · Not yet recruiting
Hospital General Universitario Dr. Balmis
Alicante, Spain · Recruiting
Hospital Universitario de Burgos
Burgos, Spain · Recruiting
Hospital San Pedro Alcántara
Cáceres, Spain · Recruiting
Complejo Hospitalario Regional Reina Sofía
Córdoba, Spain · Recruiting
Hospital Universitario de Gran Canaria Doctor Negrín
Las Palmas, Spain · Recruiting
Hospital Universitario de Canarias
Las Palmas de Gran Canaria, Spain · Recruiting
Hospital Universitario Lucus Augusti
Lugo, Spain · Recruiting
Fundación Jiménez Díaz
Madrid, Spain · Not yet recruiting
H. 12 de Octubre
Madrid, Spain · Not yet recruiting
Hospital Univeristario Ramón y Cajal
Madrid, Spain · Not yet recruiting
Hospital Virgen de la Victoria
Málaga, Spain · Recruiting
Hospital Universitario Virgen Del Rocío
Seville, Spain · Recruiting
H. Dr. Peset
Valencia, Spain · Recruiting
Hospital Universitari i Politècnic La Fe
Valencia, Spain · Recruiting
Hospital Principe de Asturias
Alcalá de Henares, Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.